History of the development of antiemetic guidelines at Mayo Clinic Rochester.

This article describes the historic experience of the development of antiemetic guidelines for patients taking chemotherapy drugs at Mayo Clinic Rochester. The initial guidelines for the use of serotonin (5-hydroxytryptamine3) receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting were developed in early 1995 and implemented in September 1995. In February 1997, the guidelines were reviewed and modified. In the spring of 1998, major changes were made based on new data from the literature and discussions with antiemetic authorities in the United States. These guidelines were implemented in July 1998. The guidelines were again reviewed and modified in December 1998. In addition, we compared costs associated with the 1997 guidelines and the December 1998 guidelines. The developed guidelines, utilizing clinically available agents, seem to provide high-quality patient care at a reasonable cost.

[1]  L. Goedhals,et al.  Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  J. Carmichael,et al.  Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis. , 1994, British Journal of Cancer.

[3]  D. Currow,et al.  Use of ondansetron in palliative medicine. , 1997, Journal of pain and symptom management.

[4]  J. Carles,et al.  Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients. , 1992, European journal of cancer.

[5]  D. Ettinger,et al.  Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Kris,et al.  Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. , 1999, The New England journal of medicine.

[7]  J. Verweij,et al.  Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  J. Hainsworth,et al.  The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  N. Gebbia,et al.  Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin‐based chemotherapy. A prospective randomized trial , 1995, Cancer.

[10]  A. Markham,et al.  Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. , 1996, Drugs.

[11]  M. Nicolson,et al.  Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? , 1991, BMJ.

[12]  F. Roila Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  J. Porta,et al.  Antiemetic efficacy of subcutaneous 5-HT3 receptor antagonists in terminal cancer patients. , 1998, Journal of Pain and Symptom Management.

[14]  M. Kris,et al.  Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. , 1997, Journal of the National Cancer Institute.

[15]  M. Kris,et al.  Proposal for classifying the acute emetogenicity of cancer chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Johnston,et al.  Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Kris,et al.  Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Y. Akahane,et al.  Transmission of HCV between spouses , 1992, The Lancet.

[19]  D. Amadori,et al.  Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Greenblatt,et al.  Current Status of Benzodiazepines , 1983 .

[21]  Philpot Cr ONDANSETRON BY SUBCUTANEOUS INFUSION , 1993 .

[22]  F. Roila,et al.  Ondansetron versus Methoclopramide, both combined with Dexamethasone, in the preventions of Cispltin induced delayed emesis. , 1997 .

[23]  D. Kerr,et al.  Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. , 1992, Oncology.

[24]  M. Aapro,et al.  Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK). , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  T. Högberg,et al.  Efficacy and tolerability of tropisetron in comparison with a combination of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin-containing chemotherapy. , 1994, European journal of cancer.

[26]  D. Greenblatt,et al.  Drug therapy. Current status of benzodiazepines. , 1983, The New England journal of medicine.

[27]  A. Favero,et al.  Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis , 1992 .

[28]  E. Perez,et al.  Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. Hainsworth,et al.  A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Kris,et al.  Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.